Comparison · NCT04865289-sae
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: serious adverse events. Trial comparisons, record NCT04865289-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04865289-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.548 | 0.434 | 0.657 | wilson | |
| Risk in group 2 | 0.304 | 0.199 | 0.433 | wilson | |
| Risk difference, group 1 minus group 2 | 0.244 | 0.0718 | 0.395 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.8 | 1.15 | 2.83 | log | |
| Odds ratio, group 1 over group 2 | 2.78 | 1.34 | 5.79 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Lenvatinib + Pembrolizumab than on Paclitaxel + Carboplatin | 4.09 | 2.53 | 13.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lenvatinib + Pembrolizumab | Participants received lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle. | 40 | 73 | EG000 |
| Group 2 | Paclitaxel + Carboplatin | Participants received paclitaxel and carboplatin once at the start of each 3-week treatment cycle. | 17 | 56 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From randomization to the date of death or last participant data collection (up to approximately 61 months).
Source ClinicalTrials.gov
Trial
- Title
- Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- NCT number
- NCT04865289
- Phases
- PHASE3
- Conditions
- Endometrial Neoplasms
- Interventions
- Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2024-10-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04865289?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04865289-sae